FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
9 letters match. Newest first.
-
DrugsZhejiang Gaorong Cosmetic Co., Ltd.
FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.
High risk -
DrugsEverlaan Organics, Inc. dba Maple Organics
FDA warns Maple Organics over OTC drug CGMP failures, unapproved new drugs, and misbranding.
High risk -
DrugsSombra Cosmetics, Inc.
FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.
High risk -
DrugsBiomic Sciences, LLC dba ION Intelligence of Nature
Biomic Sciences' nasal spray was grossly contaminated with microorganisms, and FDA also found manufacturing and labeling violations.
High risk -
FoodInmar Supply Chain Solutions, LLC
FDA found severe rodent infestation at Inmar warehouse, adulterating stored foods, over-the-counter drugs, and devices.
High risk -
DrugsGreen Pharmaceutical Co. Ltd.
FDA warns South Korea's Green Pharmaceutical over OTC drug CGMP failures, including missing identity testing and weak quality unit.
High risk -
DrugsFuller Industries Inc.
FDA warns Fuller Industries over current good manufacturing practice violations in OTC hand soaps and sanitizers, including quality oversight and ingredient testing.
High risk -
FoodAspire Pharmaceuticals, Inc.
FDA warning letter to Aspire Pharmaceuticals cites dietary supplement and drug CGMP violations, including falsified lab data and missing impurity testing.
High risk -
DrugsVitae Enim Vitae Scientific Inc.
FDA warned Vitae Enim Vitae Scientific of sterile drug CGMP violations and contamination-control failures after a 2021 inspection, leading to a recall.
High risk